Navigation Links
Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark.
Date:2/12/2008

/p>

payments 7.8 4.3

Net cash used in financing activities (212.0) (156.2)

Effect of exchange rate changes on cash 7.8 5.4

Net change in cash and cash equivalents 63.8 75.2

Cash and cash equivalents at January 1 173.8 98.6

Cash and cash equivalents at December 31 $237.6 $173.8

SIGMA-ALDRICH CORPORATION

Supplemental Financial Information - (Unaudited)

Sales Growth by Business Unit

Three Months

Ended December 31, 2007

Currency Adjusted

Reported Benefit Acquisition (Organic)

Research Essentials 11.8% 6.8% -% 5.0%

Research Specialties 15.5% 7.8% -% 7.7%

Research Biotech 11.3% 6.9% -% 4.4%

SAFC 16.8% 5.6% 8.0% 3.2%

Total 14.6% 6.8% 2.3% 5.5%

Twelve Months

Ended December 31, 2007

Currency Adjusted

Reported Benefit Acquisition (Organic)

Research Essentials 9.2% 4.6% -% 4.6%

Research Specialties 13.6% 5.3% -% 8.3%

Research Biotech 8.1% 4.4% -% 3.7%

SAFC 19.1% 4.4% 7.6% 7.1%

Total 13.4% 4.8% 2.1% 6.5%
'/>"/>

SOURCE Sigma-Aldrich Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related biology technology :

1. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
2. Sigma-Aldrich and Lab Manager Magazine Present Webinar On Laboratory Environmental, Health and Safety Compliance Strategies
3. Sigma-Aldrich Expansion in Republic of China to Support SAFC Growth
4. Sigma-Aldrich and Ingenuity Systems Announce Partnership to Create E-Commerce Search Solution Based on Biological Knowledge
5. Sigma-Aldrich to Present at the UBS 2007 Global Life Sciences Conference on September 25, 2007
6. Sigma-Aldrich Names Patrick Sullivan New VP of Research and Development for Research Biotech
7. Sigma-Aldrich and the Universite de Montreal Establish Collaboration for RNA Interference Studies
8. Sigma-Aldrich Corporations 3rd Quarter 2007 Earnings Conference Call
9. Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types
10. Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54.
11. Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 29, 2015 A ... acquiring, rapidly developing and commercialising innovative medicines ...   Highly experienced management team; blue chip ...   Mereo BioPharma Group Ltd ("Mereo"), a ... $119m ( c. £76.5m), gross, from blue chip institutional ...
(Date:7/28/2015)... 28, 2015 Seahorse Bioscience, the industry ... the provider of XF Technology which is increasingly ... areas. As the links between mitochondrial function and ... is escalating rapidly.   Recently, 12 ... Publishing Group (NPG) featuring XF Technology, including Nature, ...
(Date:7/28/2015)... Deerfield Management Company, L.P. today announced the ... will invest in groundbreaking advancements in science that may ... orphan diseases. The venture capital fund will also back ... and improve the way healthcare is delivered to patients. ... venture funds in the sector, will donate all profits ...
(Date:7/28/2015)... PRUSSIA, Pa. , July 28, 2015 ... Food and Drug Administration has accepted for review the ... recombinant factor VIII single-chain (rVIII-SingleChain) for the treatment of ... all primary endpoints. Hemophilia A ... or defective factor VIII; nearly all affected patients are ...
Breaking Biology Technology:Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 2XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 3Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3
... to design computer chips and electronic circuitry for extreme ... electrical engineers at Vanderbilt University has developed all the ... thin films of nanodiamond. They have created diamond versions ... a key element in computers., "Diamond-based devices have the ...
... Mass., Aug. 4, 2011 Interleukin Genetics, Inc. ... call and Webcast on Friday, August 12 at 9:30 a.m. ... To access the live call, dial 877-324-1976 (domestic) or 631-291-4550 ... will be available on the Investors section of Interleukin Genetics, ...
... N.J., Aug. 4, 2011 Palatin Technologies, Inc. (NYSE ... of a Phase 1 clinical trial of AZD2820, a ... a single-agent therapy for the treatment of obesity. AZD2820 ... collaborative research program with Palatin Technologies. Obesity ...
Cached Biology Technology:Designing diamond circuits for extreme environments 2Designing diamond circuits for extreme environments 3Interleukin Genetics, Inc. Announces Conference Call to Discuss Second Quarter 2011 Results 2Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca 2Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca 3
(Date:6/26/2015)... SPRINGVILLE, Utah , June 26, 2015 ATL ... assemblies and devices with specialties in single use solutions, headquartered ... acquisition of MedConx, Inc. (a California ... , and San Jose, Costa Rica ). ... Costa Rica with ATL Technology,s existing ...
(Date:6/24/2015)... , June 24, 2015 The biologics ... The major drivers for the market include growth of ... of new drug launches. Over the years, the number ... Between 2001 and 2010, the FDA approved 225 drug ... to WIPO, Europe accounted for ...
(Date:6/24/2015)... , June 24, 2015 Biometry authentication ... emerging biometric password solution one face in. ... one face in, entering the expanding ... and affordable multifactor-authentication biometric answer to the password ... provided in partnership with KeyLemon, one face in ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... MD The Federation of American Societies for ... for the Science Research Conference (SRC): Neural Mechanisms ... Research Conference, Neural Mechanisms in Cardiovascular Regulation, is ... focus on neural mechanisms that regulate normal cardiovascular ...
... Federation of American Societies for Experimental Biology (FASEB) ... Research Conference (SRC): Matricellular Proteins in Development, Health, ... surrounding extracellular matrix (ECM) are the basis for ... organization in all metazoan organisms. Structural ECM components ...
... Bethesda, MD The Federation of American Societies ... registration for the Science Research Conference (SRC): Hematologic ... Malignancies is an important and unique scientific conference ... and myeloma is presented in detail in the ...
Cached Biology News:FASEB SRC announces conference: Matricellular Proteins in Development, Health, and Disease 2
1 unit is sufficient for 1 caspase activity assay....
RABBIT ANTI WARFARIN...
Request Info...
... an agarose-digesting enzyme isolated from Pseudomonas ... bonds in agarose producing carbohydrate molecules ... remaining carbohydrate molecules will not interfere ... with Gelzyme enzyme can be used ...
Biology Products: